Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

A bio-instructive, bioactive <i>in situ</i> polymerizable wound matrix promotes scar-free burn wound repair

Aijaz A., Elloso M., Chen Y., Chogan F., Challagundla B., Rix G.

Prospective Study on Chronic Wound, Burns, Scar, published in iScience (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
iScience (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40454101
PMCID
PMC12124673
DOI
10.1016/j.isci.2025.112471
Citations
1

Abstract (original English)

Early initiation of wound regeneration and healing is the primary determinant of survival for burn patients. While superficial burns do not require secondary interventions and undergo spontaneous healing, full-thickness burns exceed the intrinsic capacity of body to induce skin regeneration. Herein, we developed a wound matrix system, referred to as PEGScarX that provides critical bioactive and bio-instructive cues to modulate cell fate decisions for burn wound healing. Our results indicate that PEGScarX promotes faster wound healing kinetics and reduces scar formation in burn wounds. PEGScarX induces fibroblast and epidermal stem cell repopulation, inhibits transdifferentiation of fibroblasts to myofibroblasts, and induces a pro-regenerative immune cell niche. These findings unravel an opportunity to reduce morbidity and mortality in burn patients due to inadequate wound regeneration and reduce the occurrence of pathological scaring.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research